VNDA News & Events

Reports Q1 revenue $51.72B, consensus $52.9M. "Vanda delivered strong commercial execution in the first quarter, highlighted by 26% growth in Fanapt sales, the groundbreaking U.S. launch of NEREUS with its pioneering direct-to-consumer platform at nereus.us, and the FDA approval of BYSANTI," said CEO Mihael Polymeropoulos. "We believe that these achievements, combined with meaningful pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation."

Vanda Pharmaceuticals announced that Nereus - tradipitant - is now commercially available across the U.S. for the prevention of vomiting induced by motion in adults, marking the first new prescription medicine approved for this condition in more than 40 years. Motion sickness affects an estimated 65 to 78 million Americans. The FDA approved Nereus on December 30, 2025, following two pivotal Phase 3 clinical trials. It offers simple dosing with just one or two capsules a day taken approximately an hour before travel.